BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,403,795 | +12.3% | 30,812 | 0.0% | 0.41% | -2.1% |
Q1 2023 | $1,249,735 | -21.9% | 30,812 | -1.8% | 0.42% | -26.6% |
Q4 2022 | $1,599,693 | -99.8% | 31,385 | +99.4% | 0.58% | +71.6% |
Q3 2022 | $847,810,000 | +79060.6% | 15,741 | -5.6% | 0.34% | -7.5% |
Q2 2022 | $1,071,000 | -29.5% | 16,667 | -14.9% | 0.36% | -12.1% |
Q1 2022 | $1,519,000 | -7.5% | 19,593 | +2.3% | 0.41% | +6.2% |
Q4 2021 | $1,643,000 | +32.3% | 19,144 | +24.0% | 0.39% | +12.5% |
Q3 2021 | $1,242,000 | -5.0% | 15,439 | -5.0% | 0.34% | -5.7% |
Q2 2021 | $1,308,000 | +16.7% | 16,248 | +22.3% | 0.37% | +5.8% |
Q1 2021 | $1,121,000 | +12.1% | 13,286 | +6.6% | 0.35% | +10.5% |
Q4 2020 | $1,000,000 | +21.5% | 12,461 | +21.8% | 0.31% | -1.6% |
Q3 2020 | $823,000 | -2.9% | 10,229 | +3.9% | 0.32% | -13.1% |
Q2 2020 | $848,000 | -35.6% | 9,847 | -39.2% | 0.37% | -42.4% |
Q1 2020 | $1,316,000 | +28.5% | 16,206 | +32.3% | 0.64% | +45.0% |
Q4 2019 | $1,024,000 | +44.8% | 12,247 | +51.6% | 0.44% | +37.3% |
Q3 2019 | $707,000 | +13.8% | 8,079 | +6.6% | 0.32% | +12.3% |
Q2 2019 | $621,000 | +51.8% | 7,579 | +50.7% | 0.28% | +45.6% |
Q1 2019 | $409,000 | – | 5,029 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |